

VIA HAND DELIVERY NOVEMBER 7, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ni et al.

Serial No.: Unassigned

Filed: Herewith

Title: Chemotactic Cytokine III

Attorney Docket No.: PF256D1C1

Group Art Unit: Unassigned

Examiner: Unassigned



INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Applicants hereby direct the Examiner's attention to references AA-AU listed on the attached Form PTO/SB/08. Copies of references AA and AU are enclosed.

Copies of references AB-AT were submitted by Applicants or cited by the Examiner in connection with related U.S. Patent Application Serial No. 08/812,003, filed March 5, 1997, now U.S. Patent No. 5,952,197, issued on September 14, 1999, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of U.S. Application No. 08/812,003, now U.S. Patent No. 5,952,197, for copies of references AB-AT.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application and consider the information contained therein during the prosecution of this application.

Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of this application are related to SEQ ID NOS:90830 and 10102 in copending U.S. Patent Application Serial No. 09/912,293. A legible copy of that

portion of U.S. Patent Application Serial No. 09/912,293 which caused it to be listed on the attached revised form PTO/SB/08 is submitted herewith as reference AA.


Applicants also wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of this application are related to SEQ ID NO:23 of copending U.S. Application No. 09/758,449, filed January 11, 2001.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b), Applicants believe that this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.

Respectfully submitted,

Date: November 7, 2001



Mark J. Hyman Reg. No. 46,789
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Phone: (240) 314-1224

MJH/LT/ba

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	Unassigned
				Filing Date	Herewith
				First Named Inventor	Ni et al.
				Group Art Unit	Unassigned
Examiner Name	Unassigned				
Sheet	2	of	2	Attorney Docket Number	PF256D1C1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	AJ	Database EST-STS on MASPARG search, WashU-Merck EST Project, (St. Louis, MO, US), No. N42961, HILLIER et al., "cDNA clone 271025 5'end," Jan. 25, 1996 (sequence alignment by International Search Authority)	
	AK	GenBank Accession No. U46326, GRESS et al., "HSU46326 Human pancreatic cancer cell line Patu 8988t Homo sapiens cDNA clone xs292"	
	AL	GenBank Accession No. N42961, HILLIER et al., "yy12d09.rl Soares melanocyte 2NbHN Homo sapiens cDNA clone IMAGE:271025 5"	
	AM	Genbank Accession No. AA160099, HILLIER et al., "zo75c08.rl Stratagene pancreas (#937208) Homo sapiens cDNA clone IMAGE:592718 5' similar to TR:E188111 PUTATIVE SURFACE GLYCOPROTEIN PRECURSOR"	
	AN	GenBank Accession No. AA157868, HILLIER et al., "zo68h04.rl Strategene pancreas (#937208) Homo sapiens cDNA clone IMAGE:592087 5' similar to TR:E188111 PUTATIVE SURFACE GLYCOPROTEIN PRECURSOR"	
	AO	GenBank Accession No. T30705, ADAMS et al., "EST21100 Human Adrenal gland Homo sapiens cDNA 5' end similar to None"	
	AP	GenBank Accession No. Z50022, YASPO et al., "H.sapiens mRNA for surface glycoprotein"	
	AQ	GenBank Accession No. Z78371, NERI et al., "HSZ78371 Human fetal brain S. Meier-Ewert Homo sapiens cDNA clone 3..153 (CEPH)"	
	AR	MIKAYAMA et al., "Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor," <i>PNAS</i> , 90:10056-10060, US, 1993	
	AS	VOET et al., <i>Biochemistry</i> , pages 126-128 and 228-234, John Wiley & Sons, Inc., 1990	
	AT	BOWIE et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions, <i>Science</i> , 247:1306-1310, 1990	
	AU	CHIEN et al., "A Novel Binding Factor Facilitates Nuclear Translocation and Transcriptional Activation Function of the Pituitary Tumor-transforming Gene Product," <i>J. Biol. Chem.</i> , 275(25):19422-19427, June 23, 2000	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	Unassigned
				Filing Date	Herewith
				First Named Inventor	Ni et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	2	Attorney Docket Number	PF256D1C1

Jc986 U.S. PTO
 09/9 6191
 11/07/01

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	AA	09/912,293		ROSEN et al.	NOT PUBLISHED
	AB	5,504,003		LI et al.	04-02-1996
	AC	5,525,486		HONJO et al.	06-11-1996

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	AD	HARA et al., "Molecular cloning and functional characterization of a novel member of the C-C chemokine family," <i>J. Immunol.</i> , 155(11):5352-5358, Dec. 1, 1995			
	AE	PROOST et al., "Human and bovine granulocyte chemotactic protein-2: complete amino acid sequence and functional characterization as chemokines," <i>Biochem.</i> , 32(38):10170-10177, Sept. 28, 1993			
	AF	LIAO et al., "Human Mig chemokine: biochemical and functional characterization," <i>J. Exp. Med.</i> , 182(5):1301-1314, Nov. 1, 1995			
	AG	LUO et al., "Biologic activities of the murine beta-chemokine TCA3," <i>J. Immunol.</i> , 153(10):4616-4624, Nov. 15, 1994			
	AH	SCHULZ-KNAPPE et al., "HCC-1, a novel chemokine from human plasma," <i>J. Exp. Med.</i> , 183(1):295-299, Jan. 1, 1996			
	AI	Database EMBL/GENBANK/DBJ on MASPARG search, Genome Analysis, Imperial Cancer Research, (London, UK), No. Z50022, YASPO, M.L., "Cloning a new gene encoding for a putative plasma transmembrane glycoprotein mapping to a human chromosome 21Q22.3," July 7, 1995 (sequence alignment by International Search Authority)			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.